Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h57 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Plaque Psoriasis Drug Forecast and Market Analysis to 2030: Focus on SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279
30 sept. 2024 09h37 HE
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This...
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11 juil. 2024 08h00 HE
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
US HUMIRA Market Projected for Extensive Growth by 2032 in Noninfectious Autoimmune Uveitis Sector
28 févr. 2024 11h05 HE
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. An insightful analysis...
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
10 janv. 2024 15h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
13 nov. 2023 09h22 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
03 oct. 2023 13h57 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
14 sept. 2023 11h37 HE
|
Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
31 août 2023 16h35 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent...
Pfizer, Amneal Pharmaceuticals, and Merck & Co. Lead the Global Muscle Relaxant Drugs Market with Innovative Drug Offerings and Strong Market Presence
01 août 2023 09h28 HE
|
Research and Markets
Dublin, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The "Muscle Relaxant Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global muscle relaxant drugs market...